Tag:
acute lymphoblastic leukemia
Latest Headlines
Latest Headlines
Jazz Pharma snaps up Eusa in $700M buyout deal
The Ireland-based drugmaker ($JAZZ) says it will shell out $650 million upfront and potentially $50 million more to scoop up Eusa Pharma and its drugs for cancer and critical care.
New drug for rare leukemia wins FDA panel vote with limited data
Talon Therapeutics ($TLON) took one more tentative step closer to a possible FDA approval of its cancer drug Marqibo yesterday, winning a 7-to-4 vote among a group of the agency's oncology advisers.
Astex hammered after regulators diss Dacogen application
Shares of Astex Pharmaceuticals ( $ASTX ) got hammered yesterday after regulators turned a skeptical eye on Eisai 's request for an expanded use of Dacogen , a leukemia-related drug the biotech licensed
UPDATED: Amgen scoops up Micromet tumor-fighting pipeline for $1.2B
Not to be left out of the M&A rush, Amgen said this morning that it will buy German/U.S. cancer drug developer Micromet ( $MITI ) for $1.16 billion in cash. At $11 a share, the deal gives its
FDA stamps approval on Eusa Pharma's orphan leukemia drug
U.S. regulators have given a market green light for Eusa Pharma 's enzyme drug Erwinaze for a subset of patients with acute lymphoblastic leukemia who have immune reactions to an existing version of
Micromet drug shows promise against severe blood cancer
While there's a way to go in proving the mettle of the drug, Micromet's experimental antibody blinatumomab wiped out cancer cells in nine of 12 patients with relapsed acute lymphoblastic leukemia
